Egan Mary
Director · URBN, NDLS
As of 2026-09-16, Egan Mary has 11 Form 4 transactions on record across 2 companies — 5 in the trailing 12 months.
Everything this person has disclosed to the SEC on Form 4 — across every company they file for — reconstructed from the public record. A filing history, not a tip sheet.
Pattern in the record: open-market sales filed in September in multiple years since 2025 — a recurring calendar cadence, more consistent with scheduled activity than a one-off decision.
Reconstructed holdings
Reconstructed from this person's own Form 4 filings — the total each filing reported owning afterward, priced at the close on the as-of date shown. A filed position can lag the real one.
Direct and indirect holdings (e.g. through a trust or fund) are tagged separately, as filed.
Trades by company
Filing ledger
| Date | Company | Action | Shares @ price | Value | Ownership Δ | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | URBN | Sale | 650 @ $78.48 | $51K | −4.0% of holding | 15,700 | Form 4 |
| 2025-09-10 | URBN | Sale | 1,000 @ $70.12 | $70K | −6.6% of holding | 14,250 | Form 4 |
9 award / exercise / gift records — not counted as purchases
| Date | Company | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|
| 2026-06-03 | URBN | Award / grant | 2,100 | 2,100 | Form 4 |
| 2026-06-02 | URBN | Option exercise | 2,100 | 0 | Form 4 |
| 2026-06-02 | URBN | Option exercise | 2,100 | 16,350 | Form 4 |
| 2026-06-02 | URBN | Option exercise | 2,100 | 16,350 | Form 4 |
| 2025-06-04 | URBN | Award / grant | 2,100 | 0 | Form 4 |
| 2025-06-03 | URBN | Option exercise | 3,700 | 0 | Form 4 |
| 2025-06-03 | URBN | Option exercise | 3,700 | 15,250 | Form 4 |
| 2025-06-03 | URBN | Option exercise | 3,700 | 15,250 | Form 4 |
| 2025-05-15 | NDLS | Award / grant | 36,000 | 132,439 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.